While the studies – IMbark and IMerge – are both still ongoing investors were spooked by the news that Janssen was going to drop the lower dose arm in one of them, IMbark, in myelofibrosis. Imetelstat is Geron Corp.’s only real pipeline asset.
Janssen R&D LLC is conducting the two late-stage trials of the telomerase inhibitor following a licensing deal signed back in November 2014. The deal was a boon for the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?